Why argenx Stopped the UplighTED Trial of Efgartigimod (VYVGART) for Thyroid Eye Disease

If you’ve been following thyroid eye disease research, you may have seen recent news about the UplighTED study by argenx being stopped early. I’ve received questions, concerns, confusion, and understandably a lot of disappointment.

So let’s walk through what actually happened, what it means for people living with TED, and where research is still moving forward.

First, what was this study?

The UplighTED study was testing a medication called efgartigimod (VYVGART SC) for people with moderate to severe Thyroid Eye Disease (TED).

The goal was to see whether lowering certain immune antibodies could improve eye symptoms like bulging, double vision, and quality of life.

Official press release here.

Why was the study stopped?

The simple answer:

The medication was safe, but it didn’t work well enough.

At a planned midpoint (24 weeks), an independent data monitoring committee revi

ewed the results and found that:

  • Too few patients had meaningful improvement in eye bulging

  • The drug was unlikely to meet its main goal even if the study continued

Because of that, the trial was stopped early for what’s called futility.

What does “futility” actually mean?

This word sounds scary and they keep repeating it, but in research it has a very specific meaning.

It does not mean:

  • The drug was dangerous

  • Patients were harmed

  • The study was poorly run

It simply means: that based on the data so far, continuing the study was very unlikely to lead to success.

Was it stopped for safety reasons?

No.

  • There were no new safety concerns

  • The medication was well tolerated

  • Patients were not stopped due to side effects

The issue was effectiveness, not safety.

Why antibody-lowering therapies don’t always improve eye symptoms

This is one of the most important takeaways from this study.

Thyroid Eye Disease is not just a blood antibody problem.

While antibodies like TSI and TRAb play a role, eye symptoms are driven by what’s happening inside the orbit, including:

  • Activation of orbital fibroblasts

  • Expansion of fat and muscle tissue

  • Inflammatory signaling that becomes self-sustaining

  • Structural tissue changes that may not reverse easily

Once these processes are active, simply lowering circulating antibodies may not be enough to:

  • Reduce eye bulging

  • Reverse tissue remodeling

  • Improve double vision

This is especially true if treatment is started later in the disease course.

In other words:
Lowering antibodies can help some autoimmune conditions, but TED often requires therapies that directly target orbital inflammation and tissue behavior.

This study reinforces what many clinicians and patients already experience in real life, that antibody levels and eye symptoms don’t always move together.

So what research is still happening in TED?

Even though this study was stopped, TED research is very much ongoing.

Current areas of focus include:

  • Targeting orbital fibroblasts directly, which are key drivers of eye bulging and tissue expansion

  • Blocking inflammatory signaling pathways involved in active TED

  • Improving treatments for chronic or inactive TED, where tissue changes persist

  • Exploring combination approaches, rather than single-target therapies

  • Refining treatment timing, especially earlier intervention during the active phase

There is also growing interest in:

  • Understanding why some patients respond to certain therapies and others don’t

  • Identifying subtypes of TED rather than treating it as one disease

  • Developing safer, more targeted options with fewer long-term risks

Progress can feel slow, but each study adds clarity about what works, what doesn’t, and why.

What this means for people living with TED

I know this kind of news can feel discouraging. Many of us are watching research closely, hoping for better options.

Here’s what this does and does not mean:

It does mean:

  • This medication will not move forward as a TED treatment

  • Lowering antibodies alone may not be enough for eye symptom improvement

It does NOT mean:

  • All immune-based therapies won’t work

  • TED research is failing

  • You’re out of options or hope

Every study, even ones that stop early, helps move the field forward.

My honest take

TED is complex. It’s not just thyroid labs. It’s not just antibodies. And it’s not the same for everyone.

This study reminds us that meaningful TED treatments must address:

  • Tissue-level inflammation

  • Orbital biology

  • Timing, severity, and individual variability

  • ROOT CAUSES

And it reinforces why nuanced, personalized care matters so much.

If you’d like me to write next about:

  • How this compares to Tepezza

  • Active vs inactive TED and why timing matters

  • Why labs can look “better” while eye symptoms don’t

  • How I think about integrative support alongside conventional care

You can reply to this post or message me. I’m here, and I’ll keep translating the science into something that actually makes sense.

Disclaimers

This post is for educational and awareness purposes only. I’m sharing both research and my personal experience with thyroid eye disease and autoimmunity. It is not medical advice and should not replace individualized guidance from your doctor, pharmacist, or other qualified healthcare provider. Please do not start, stop, or change any treatments, supplements, or vaccines without consulting your own care team. Everyone’s body and medical history are unique — what I share here is meant to spark conversation, not to dictate your personal health decisions.

Some product links included in this post may be affiliate links. This means that if you purchase through them, I may earn a small commission at no additional cost to you. I only share products I personally use and love, and all opinions are entirely my own.

—-

If you’re reading this, maybe your world has also been flipped upside down by a diagnosis. Maybe you’re searching for the missing pieces, for someone who sees you as more than numbers on a chart.

I am here sharing my Graves & TED story, spilling all of the valuable information and secrets I’ve found, and the beginning of this space. Thank you for being here. Please say hi, I’d love to meet you!! - Elena

Join my free monthly support group to connect with others with Graves & TED: Community Support Group

Download my Thyroid Healing Bundle: BUNDLE 

Fullscript supplement formulary 10% off everything: https://us.fullscript.com/welcome/elena

Book a 1:1 visit with me: Book here

Previous
Previous

How To Connect With Others Living With Graves Disease and Thyroid Eye Disease…Join Our monthly Virtual Support Group

Next
Next

Subacute Thyroiditis: Causes, Symptoms, and Healing Through an Integrative and Functional Medicine Lens